A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Phase of Trial: Phase II/III
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Hereditary nephritis
- Focus Registrational; Therapeutic Use
- Acronyms CARDINAL
- Sponsors Reata Pharmaceuticals
- 23 Jul 2018 Results presented in the Reata Pharmaceuticals media release.
- 08 May 2018 According to a Reata Pharmaceuticals media release, full enrolment is expected in the second half of 2018. One-year eGFR withdrawal data from the Phase 2 portion of this study will be available in the third quarter of this year.
- 11 Apr 2018 Results published in the Reata Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History